Norstella

Norstella introduces NorstellaLinQ: https://ow.ly/nqga50TGawG. It's biopharma’s first fully integrated data asset combining RWD—open and closed claims, lab results and EMR—with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Get closer to the patient than ever before. Learn more about NorstellaLinQ at the link in this post.

Artificial intelligence is transforming pharmaceutical R&D. https://ow.ly/VefQ50TL4B5 Norstella’s 2024 survey of 125 senior life sciences decision-makers reveals how AI is being adopted, the benefits and challenges faced, and future expectations. Stay ahead in pharmaceutical R&D with the latest AI trends by downloading the infographic at the link in this post. #Pipeline2Patient #FollowNorstella #Pharma #LifeSciences

Conference Catch-Up: Navigating the Evolving CDMO Landscape - Listen now: https://ow.ly/Atex50U5al4 CDMOs are transforming pharmaceutical production, enhancing speed, flexibility, and efficiency. At CPHI Milan, we observed key trends and celebrated excellence at Citeline’s 11th Annual Global Generics & Biosimilars Awards. After the conference, Andrea Charles, VP of Custom Content at Norstella, Andrew Warmington, Manufacturing Editor at Citeline, and Izabela Chmielewska, Managing Editor of Custom Content, discussed key takeaways, including the BIOSECURE Act and advancements in biomanufacturing.

Dive into the latest insights from our top experts and stay updated with the most recent developments in market access.

Connect with us at ASH 2024 in San Diego! https://ow.ly/m48X50U9rao Join us this December 7-10 when Jennifer (Goldenberg) Klarer, M.Sc.Eng., Managing Partner at The Dedham Group, will be on-site to showcase how we empower cell and gene therapy manufacturers to excel in commercialization and access strategies. Discover our custom solutions designed to drive market success. Don’t miss this opportunity—book your meeting with Jennifer today! #ASH #ASH24

Congratulations Norstella 🥳

We did it! Norstella is thrilled to be named "Company of the Year" by the Business Intelligence Group in the 2024 BIG Awards for Business. https://ow.ly/NXwP50UbhZa This prestigious recognition highlights our relentless efforts to reshape our industry and our unwavering commitment to smoothing the path to lifesaving therapies for patients and providers. Learn more in the news release from Business Intelligence Group: https://ow.ly/Jmwn50UbhZ9.

https://ow.ly/CKG750UapAa Discover how leading pharmaceutical companies leverage MMIT's powerful Analytics platform to gain seamless access to comprehensive formulary information, medical policies, and restriction details. Download our case studies to see how our user-friendly technology drives industry success at the link in this post.

Employee Spotlight: Meet Melody Marden https://ow.ly/NHGw50U7tE9 Melody is an industry veteran who currently holds the role of Vice President, Custom Solutions at Evaluate Ltd. While Melody has had a long and diverse career in healthcare, working across the spectrum of pharma and life science organizations, she has always stayed true to her driving mantra: Strive to make a difference. View the full Q&A at the link in this post. #FollowNorstella #Pipeline2Patient

📣SMBC Nikko Securities × CITELINE collabo webinar📣 ~Clinical Trends in nucleic-acids-therapeutics~ *Japanese webinar The SMBC Nikko Securities collaboration webinar, which was attended by over 1000 people last time, will be held on the topic of 【nucleic acid medicine】. Mr. Jiro Fujiyasu, Director of Pharmaceuticals & Healthcare, Industry Research Department, SMBC Nikko Securities Inc. will give a presentation on the latest trends in nucleic acid drugs from an expert's perspective. 〇date; 27th Dec 2PM JST 〇registration; zoom[free] 〇language; japanese Details HERE ; https://lnkd.in/gtjTQ5eF